Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Taco Bell is re-upping its value menu game with the introduction of $5, $7 and $9 luxe cravings boxes, while TikTok is ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

Below is a roundup of payer-centric news headlines you may have missed during the month of January 2025. | You may have ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

A health alert was issued for certain frozen Walmart empanadas that were mislabeled, which could pose a risk for some people ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

The House Ways and Means Committee in the US voted in favour of a new bill which would end a two-decade-long restriction on the coverage of drugs to treat obesity under Medicare. The Treat and ...